Mammary Cell News 11.01 January 17, 2019 | |
| |
TOP STORYScientists demonstrated that cancer cell plasticity could be exploited therapeutically by forcing the trans-differentiation of epithelial-mesenchymal transition-derived breast cancer cells into post-mitotic and functional adipocytes. [Cancer Cell] Full Article | Press Release | Graphical Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Investigators identified 63 protein kinases exhibiting altered expression and/or phosphorylation in Src-transformed mammary epithelial cells. An integrated siRNA screen identified nine kinases, including SGK1, as being essential for Src-induced transformation. [Nat Commun] Full Article Exosomes from Nischarin-Expressing Cells Reduce Breast Cancer Cell Motility and Tumor Growth When co-cultured on exosomes from Nischarin-positive cells, breast cancer cells exhibited reduced survival, migration, adhesion, and spreading. The same co-cultures formed xenograft tumors of significantly reduced volume following injection into mice. [Cancer Res] Abstract Researchers showed that c-myc was a transcriptional target of p53 in mammary stem cells and was activated in breast tumors as a consequence of p53 loss. [Cell Rep] Full Article | Graphical Abstract Scientists found that higher SEPW1 expression due to downregulation of PIWI-interacting RNA (piRNA)-36,712 in breast cancer may suppress P53, leading to upregulated Slug but decreased P21 and E-cadherin levels, thus promoting cancer cell proliferation, invasion and migration. [Mol Cancer] Full Article BAD stimulated mitochondrial oxygen consumption in a novel manner that was downstream of substrate entry into the mitochondria. BAD stimulated complex I activity that facilitated enhanced cell growth and sensitized cells to apoptosis in response to complex I blockade. [Oncogene] Full Article Utilizing an antibody against myeloid zinc finger-1-pS27, investigators showed that the phosphorylation of S27 correlated significantly with high-level expression of ErbB2 in primary invasive breast tumors. [Oncogene] Abstract Knocking down MDMX or MDM2 in MDA-MB-231 cells reduced cell migration and circulating tumor cell detection, but only MDMX knockdown reduced tumor volumes at early time points. [Breast Cancer Res] Full Article Argonaute 2 Drives miR-145-5p-Dependent Gene Expression Program in Breast Cancer Cells The authors showed that miR-145-5p and argonaute 2 (Ago2) protein were concomitantly downregulated in breast cancer (BC) tissues and that restoration of miR-145-5p expression in BC cells led to Ago2 protein induction through the loosening of Ago2 mRNA translational repression. [Cell Death Dis] Full Article Growth hormone receptor silencing drastically reduced the chemoresistant and metastatic behavior of estrogen receptor negative breast cancer cells and also inhibited the AKT/mTOR pathway. [Exp Mol Med] Full Article Metastasis-associated protein 1 (MTA1) overexpression downregulated MTA2 expression at the protein level rather than the mRNA level. Neutrophil elastase was predicted to cleave MTA2 and was responsible for MTA1 overexpression-induced MTA2 degradation. [Cell Commun Signal] Full Article Subscribe to one of our other 19 science newsletters such as Prostate Cell News & ESC & iPSC News. | |
| |
REVIEWSG-Protein Coupled Estrogen Receptor in Breast Cancer The authors discuss the G-protein coupled estrogen receptor, its role in breast cancer, and the interactions with the estrogen receptor and epidermal growth factor receptor. [Int J Mol Sci] Abstract | Full Article | Graphical Abstract Visit our reviews page to see a complete list of reviews in the mammary cell research field. | |
| |
INDUSTRY NEWSTRIO Enrolls First Patient into Phase III NATALEE Clinical Trial Translational Research In Oncology (TRIO), in collaboration with Novartis and under the direction of Dennis Slamon, MD, PhD, TRIO Chairman/Executive Director and Director of Clinical Translational Research at the University of California, Los Angeles Jonsson Comprehensive Cancer Center, announced the enrollment of the first patient into its newest clinical trial, NATALEE. [Translational Research In Oncology] Press Release Daiichi Sankyo Company, Limited announced that the first patient has been dosed in DESTINY-Breast04, a global pivotal Phase III study evaluating the safety and efficacy of [fam-] trastuzumab deruxtecan, an investigational HER2 targeting antibody drug conjugate, in patients with HER2 low, unresectable and/or metastatic breast cancer previously treated with standard chemotherapy. [Daiichi Sankyo Company, Limited] Press Release Puma Biotechnology filed a new drug submission for NERLYNX® with Health Canada in July 2018 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy. [Puma Biotechnology, Inc. (Business Wire, Inc.)] Press Release $9 Million Supports Deep Dive into Breast, Pancreatic Cancers Washington University School of Medicine in St. Louis has received a $9 million grant from the National Institutes of Health to study the life histories of breast and pancreatic cancers. [Washington University in St. Louis] Press Release | |
| |
POLICY NEWSGerman Institutions and Wiley Reach Open-Access Publishing Deal After nearly three years of contract negotiations, a consortium of nearly 700 German libraries, research institutes, and universities called Project DEAL has forged an agreement with the scholarly publisher Wiley that moves the publishing industry towards more open access. [The Scientist] Editorial How UK Scientists Are Planning for a Chaotic No-Deal Brexit British scientists are ramping up preparations for a ‘no deal’ Brexit on 29 March – a situation that would instantly affect travel, data collection, clinical trials and crucial laboratory supplies. [Nature News] Editorial
| |
EVENTSNEW Cell Symposia: Hallmarks of Cancer Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Fellowship – Breast Cancer (Cold Spring Harbor Laboratory) NEW Postdoctoral Fellowship – Cancer Research (North Carolina Central University) NEW Postdoctoral Fellowship – Breast Cancer (University of Bergen) Postdoctoral Fellow – Breast Cancer Research (City of Hope) Faculty Position – Molecular Cancer Biology (University of Pittsburgh) Faculty Position – Breast Cancer (University of Texas MD Anderson Cancer Center) Postdoctoral Associate – Cancer (University of Miami) Postdoctoral Position – Breast Cancer (Northwestern University) Research Associate – Breast Single Cell Atlas (University of Cambridge) Research Assistant – Breast Medical Oncology (MD Anderson Cancer Center) Associate Researcher – Breast Cancer Biology (Icahn School of Medicine at Mount Sinai) Master’s Student – Stem Cell Biology and Cancer (Helmholtz-Center München) Postdoctoral Position – Novel Cancer Gene and Therapy (University of Notre Dame) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Mammary Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|